Hims & Hers Health/$HIMS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Hims & Hers Health
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
- Ticker
- $HIMS
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 2,442
- Headquarters
- San Francisco, United States
- Website
- www.hims.com
HIMS Metrics
BasicAdvanced
$6.9B
-
-$0.62
2.42
-
Price and volume
Market cap
$6.9B
Beta
2.42
52-week high
$48.34
52-week low
$13.74
Average daily volume
10M
Financial strength
Current ratio
0.934
Quick ratio
0.82
Long term debt to equity
4.736
Total debt to equity
4.771
Interest coverage (TTM)
-10.44%
Profitability
EBITDA (TTM)
-10.177
Gross margin (TTM)
69.53%
Net profit margin (TTM)
-5.51%
Operating margin (TTM)
-3.78%
Effective tax rate (TTM)
13.19%
Revenue per employee (TTM)
$1,060,000
Management effectiveness
Return on assets (TTM)
-2.21%
Return on equity (TTM)
-32.03%
Valuation
Price to revenue (TTM)
2.628
Price to book
21.36
Price to tangible book (TTM)
-5.77
Price to free cash flow (TTM)
109.948
Free cash flow yield (TTM)
0.91%
Free cash flow per share (TTM)
0.27
Growth
Revenue change (TTM)
28.04%
Earnings per share change (TTM)
-178.84%
3-year revenue growth (CAGR)
53.65%
3-year earnings per share growth (CAGR)
39.88%
What the Analysts think about HIMS
Analyst ratings (Buy, Hold, Sell) for Hims & Hers Health stock.
Analyst projections of the future price of Hims & Hers Health stock.
Bulls say / Bears say
Q2 revenue rose 38% year on year and subscribers grew 19% to nearly 2.9 million. Hims also raised its 2026 revenue outlook, showing that growth has re-accelerated after a weak first quarter. (Reuters, Hims & Hers)
Eucalyptus gives Hims an established presence across several overseas markets, and the Australia launch extends its reach into Asia-Pacific. International revenue grew more than 17-fold in Q2, offering a potential second growth engine beyond the US. (Hims & Hers, Hims & Hers)
Hims has a route to remain in the weight-loss market through branded, approved medicines: it partnered with Novo Nordisk to offer Wegovy as regulators moved to restrict mass compounding of GLP-1 drugs. This may help it retain exposure to strong demand without relying solely on copycat products. (Reuters, Reuters)
The growth is coming with weaker economics: Q2 gross margin fell to 64% from 76% a year earlier, and the company reported a wider loss as branded weight-loss drugs and expansion raised costs. Management expects margin pressure to persist in the second half and does not expect a return to profitability until 2027. (Reuters, Hims & Hers)
Regulatory action has already forced Hims to reverse its launch of a compounded semaglutide pill, and the FDA has proposed further limits on bulk compounding of popular GLP-1 drugs. That leaves less room for the lower-cost copycat products that helped build its weight-loss offering. (Reuters, Reuters)
International expansion is not yet a proven earnings driver: management expects the business to operate at or near break-even in 2026 while it prioritises scale. Hims also raised $350 million through convertible notes to support expansion and technology investment, bringing financing and potential dilution risk before overseas growth delivers stronger profits. (EarningsCalls.dev, Hims & Hers)
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2026.
HIMS Financial Performance
Revenues and expenses
HIMS Earnings Performance
Company profitability
Upcoming events
No upcoming events
HIMS News
AllArticlesVideos
HIMS CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Hims Investors of Securities Class Action Lawsuit Deadline on November 2, 2026
Newsfile Corp6 hours ago
Kaplan Fox Advises Hims & Hers Health, Inc. (HIMS) Investors of a Pending Securities Fraud Lawsuit - Deadline is November 2, 2026
Newsfile Corp11 hours ago
HIMS FINAL DEADLINE NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - HIMS
Newsfile Corp20 hours ago
Funds containing HIMS
AllUSDEURGBP
Fund name | Fund size | $HIMS weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.49% |
iShares Ageing Population£AGES | $953M | 0.49% |
iShares Ageing Population€AGED | $903M | 0.49% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.21% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.21% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.